Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial

被引：2
|
作者：
Lucchese B.
机构：
来源：
Nature Reviews Nephrology | 2010年 / 6卷 / 7期
关键词：
D O I：
10.1038/nrneph.2010.72
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：383 / 383
相关论文
共 50 条
  • [1] Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?
    Katsi, Vasiliki
    Skalis, Georgios
    Pavlidis, Antonis N.
    Makris, Thomas
    Nihoyannopoulos, Petros
    Tousoulis, Dimitris
    Kallikazaros, Ioannis
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2015, 1 (04) : 260 - 264
  • [2] The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial
    Solomon, Scott D.
    Zile, Michael
    Pieske, Burken
    Voors, Adriaan A.
    Shah, Amil
    Kraigher-Krainer, Elisabeth
    Shi, Victor
    Bransford, Toni
    Takeuchi, Madoka
    Gong, Jianjian
    Lefkowitz, Martin
    Packer, Milton
    McMurray, John J. V.
    JOURNAL OF CARDIAC FAILURE, 2012, 18 (11) : 883 - 883
  • [3] Efficacy of LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in obese and overweight subjects with hypertension
    Ruilope, L. M.
    Izzo, J. L., Jr.
    Conde, L. G.
    Zappe, D. H.
    Zhang, Y.
    Zhang, J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 65 - 65
  • [4] Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
    Gu, Jessie
    Noe, Adele
    Chandra, Priya
    Al-Fayoumi, Suliman
    Ligueros-Saylan, Monica
    Sarangapani, Ramesh
    Maahs, Suzanne
    Ksander, Gary
    Rigel, Dean F.
    Jeng, Arco Y.
    Lin, Tsu-Han
    Zheng, Weiyi
    Dole, William P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04): : 401 - 414
  • [5] Phase II PARAMOUNT trial of LCZ696
    Bryony M. Mearns
    Nature Reviews Cardiology, 2012, 9 (11) : 612 - 612
  • [6] Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor
    Gan, Lu
    Langenickel, Thomas
    Petruck, Jesika
    Kode, Kiran
    Rajman, Iris
    Chandra, Priya
    Zhou, Wei
    Rebello, Sam
    Sunkara, Gangadhar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (01): : 78 - 86
  • [7] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Boggarapu, Sreedevi
    Sunkara, Gangadhar
    CLINICAL PHARMACOKINETICS, 2017, 56 (12) : 1461 - 1478
  • [8] PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF LCZ696, A NOVEL DUAL-ACTING ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI)
    Gu, J.
    Noe, A.
    Chandra, R.
    Al-Fayoumi, S.
    Ligueros, M.
    Sarangapani, R.
    Maahs, S.
    Ksander, G.
    Rigel, D.
    Jeng, A.
    Dole, W.
    JOURNAL OF HYPERTENSION, 2009, 27 : S9 - S9
  • [9] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    Clinical Pharmacokinetics, 2017, 56 : 1461 - 1478
  • [10] Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor–Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    Clinical Pharmacokinetics, 2018, 57 : 105 - 123
12345